SIOC 中文
CJOG
Adv search

Chinese Journal of Organic Chemistry >

2022 , Vol. 42 >Issue 9: 2988 - 2993

DOI: https://doi.org/10.6023/cjoc202203044

NOTES

New Routes to Antiviral Molnupiravir against SARS-CoV-2 Infection

  • Zheng Liu ,
  • Jing Yang ,
  • Fengwu Liu
Expand
  • a College of Chemistry, Jilin University, Changchun 130012
    b Institute for Drug Research, Zhengzhou University, Zhengzhou 450001
    c School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001
* Corresponding author. E-mail:

Received date: 2022-03-22

  Revised date: 2022-05-18

  Online published: 2022-06-09

Fold

Abstract

Molnupiravir is an oral drug against SARS-CoV-2 infection approved by Britain and America in 2021. Currently, the reported synthetic methods of molnupiravir have disadvantages, such as long steps, limited yield and high cost. Efficient methods for the synthesis of molnupirovir through direct acylation of low-price cytidine are developed. In different proportions of aqueous tetrahydrofuran solution, selective isobutyrylation of hydroxyl of cytidine and further 2',3'-deprotection of 2',3',5'-tri-O-isobutyrylcytidine could be realized, which successfully gave 5'-O-isobutyrylcytidine. Finally, N4-hydroxylation of 5'-O-isobutyrylcytidine yielded molnupirovir. Using this straightforward and high-yielding three-step approach, molnupirovir was obtained from cytidine in 82% overall yield.

Key words： molnupiravir; antiviral; SARS-CoV-2; selective isobutyrylation; cytidine

Cite this article

Zheng Liu , Jing Yang , Fengwu Liu . New Routes to Antiviral Molnupiravir against SARS-CoV-2 Infection[J]. Chinese Journal of Organic Chemistry, 2022 , 42(9) : 2988 -2993 . DOI: 10.6023/cjoc202203044

References

[1]
Rosenke, K.; Hansen, F.; Schwarz, B.; Feldmann, F.; Haddock, E.; Rosenke, R.; Barbian, K.; White, K. M.; Okumura, A.; Leventhal, S.; Hawman, D. W.; Ricotta, E.; Bosio, C. M.; Martens, C.; Saturday, G.; Feldmann, H.; Jarvi, M. A. Nat. Commun. 2021, 12, 2295.
[2]
(a) Painter, G. R.; Bluemling, G. R.; Natchus, M. G.; Guthrie, D. WO 2019113462, 2018.
[2]
(b) Painter, G. R.; Perryman, D.; Bluemling, G. R. WO 2019173602, 2019.
[3]
Gopalsamuthiram, V. R.; Kadam, A. L.; Noble, J. K.; Snead, D. R.; Williams, C. T.; Jamison, T. F.; Senanayake, C.; Yadaw, A.; Roy, S.; Sirasani, G.; Gupton, F. B.; Burns, J. M.; Cook, D. W.; Stringham, R. W.; Ahmad, S.; Krack, R. Org. Process Res. Dev. 2021, 25, 2679.
[4]
Gopalsamuthiram, V. R.; Williams, C.; Noble, J.; Jamison, T. F.; Gupton, B. F.; Snead, D. R. Synlett 2021, 32, 326.
[5]
Vasudevan, N.; Ahlqvist, G. P.; McGeough, C. P.; Paymode, D. J.; Cardoso, F. S.; Lucas, T.; Dietz, J.-P.; Opatz, T.; Jamison, T. F.; Guptona, F. B.; Snead, D. R. Chem. Commun. 2020, 56, 13363.
[6]
Nishino, S.; Rahman, A.; Takamura, H.; Ishido, Y. Tetrahedron 1985, 41, 5503.
[7]
Harrington, P. J.; Hildbrand, S.; Sarma, K. WO 2008071571, 2008.
[8]
Kumar, A. B.; Manetsch, R. J. Org. Chem. 2014, 17, 3551.
Options
Outlines

/

〈 〉